Ovits Channa G, Amin Bijal D, Halverstam Caroline
J Drugs Dermatol. 2017 Jul 1;16(7):701-704.
Epidermodysplasia verruciformis (EV) is a rare inherited dermatosis characterized by increased susceptibility to human papilloma virus infection. Acquired EV occurs in patients with compromised cell-mediated immunity, such as patients with HIV and transplant recipients. Optimal management of acquired EV has not yet been established, as cases are rare and are due to a variety of underlying conditions. Additionally, no distinctions have been made between different immunosuppressive medications and their respective link to EV.
We report a patient with systemic lupus erythematosus who developed EV while on azathioprine and prednisone. The patient's lesions resolved completely after she was switched from azathioprine to mycophenolate mofetil. Her lesions recurred when her immunosuppressive regimen was again changed from mycophenolate mofetil to methotrexate. A review of the literature revealed azathioprine to be related to other cases of acquired EV.
This case indicates a possible link between specific immunosuppressive drugs and the development of EV, allowing for new EV treatment considerations. In this case and previous cases, azathioprine is indicated as being particularly linked with the development of EV, while mycophenolate mofetil may be an immunosuppressive option that is less likely to induce EV in patients predisposed to this condition. J Drugs Dermatol. 2017;16(7):701-704.
疣状表皮发育不良(EV)是一种罕见的遗传性皮肤病,其特征是对人乳头瘤病毒感染的易感性增加。获得性EV发生在细胞介导免疫受损的患者中,如艾滋病毒患者和移植受者。由于病例罕见且病因多样,获得性EV的最佳治疗方法尚未确立。此外,不同的免疫抑制药物及其与EV的各自关联尚未明确区分。
我们报告了一名系统性红斑狼疮患者,在使用硫唑嘌呤和泼尼松期间发生了EV。当患者从硫唑嘌呤换用霉酚酸酯后,其皮损完全消退。当她的免疫抑制方案再次从霉酚酸酯改为甲氨蝶呤时,皮损复发。文献回顾显示硫唑嘌呤与其他获得性EV病例有关。
该病例表明特定免疫抑制药物与EV的发生之间可能存在关联,为EV的新治疗考虑提供了依据。在本病例及之前的病例中,硫唑嘌呤被认为与EV的发生特别相关,而霉酚酸酯可能是一种免疫抑制选择,在易患此病的患者中诱导EV的可能性较小。《药物皮肤病学杂志》。2017年;16(7):701 - 704。